This site contains promotional content intended for UK Healthcare Professionals and other relevant decision makers | Not a HCP? Visit our Public Site.
Adverse Event reporting can be found at the bottom of the page | Prescribing Information for the relevant medicine can be found adjacent to the below content and/or in the footer below.
HCC treatment
Continue their journey for as long as possible with Nexavar® (sorafenib) then Stivarga® (regorafenib)
Over the past decade, first-line Nexavar has established itself as the standard of care for patients with unresectable HCC by offering increased median overall survival (OS) vs. placebo. Stivarga is the only second-line treatment to be recommended by NICE and accepted for use by the SMC for patients with advanced or metastatic HCC who have tolerated and progressed on Nexavar.
Nexavar then Stivarga, in sequence, have the potential to improve outcomes in your HCC patients (vs Nexavar then placebo) and help you to continue what you started.
Discover how you can learn about survival benefit of your patients with HCC while potentially optimising quality of life by clicking on the relevant treatment goal below.
Nexavar is indicated for the treatment of adult patients with HCC while Stivarga is indicated for the treatment of adult patients with HCC who have been previously treated with Nexavar.
Which aspect of treatment are you interested in?
Mechanism of action
Nexavar is a multikinase inhibitor which has demonstrated both anti-proliferative and anti-angiogenic properties in vitro
Abbreviations: BRAF: B-Raf proto-oncogene; serine/threonine kinase; CRAF: C-Raf proto oncogene serine/threonine kinase; c-KIT: c-KIT, c-V-kit Hardy-Zuckerman 4 feline sarcoma viral oncogene homolog; FLT: fms-like tyrosine kinase; PDGFR: platelet-derived growth factor receptor; RET: rearranged during transfection; VEGFR: vascular endothelial growth factor receptor.
PP-NEX-GB-0224 | March 2025
- Referencesexpand_more
- 1Finn RS et al. J Hepatol 2018;69(2):353-358.
- 2Llovet JM et al. N Engl J Med 2008;359(4):378-390
- 3Personeni N et al. Drugs Context 2018;7:212533.
- 4Vogel A et al. Ann Oncol 2018;29(4):iv238-iv255.
- 5National Institute for Health and Care Excellence (NICE) guidance. Sorafenib for treating advanced hepatocellular carcinoma. Available at: https://www.nice.org.uk/guidance/ta474 (Last Accessed February 2024)
- 6National Institute for Health and Care Excellence (NICE) guidance. Regorafenib for previously treated advanced hepatocellular carcinoma. Available at: https://www.nice.org.uk/guidance/ta555 (Last Accessed February 2024)
- 7Scottish Medicines Consortium. 2018. Advice 1316/18. Available at: https://www.scottishmedicines.org.uk/medicines-advice/regorafenib-stivarga-fullsubmission (Last Accessed February 2024)
- 8Bruix J et al. Lancet 2017;389(10064):56-66.
- 9Nexavar (sorafenib) Summary of Product Characteristics.
- 10Stivarga (regorafenib) Summary of Product Characteristics. Available at: www.medicines.org.uk (Last Accessed February 2024)
- 11Broecker-Preuss M et al. BMC Cancer 2015;15:184-196.
- 12Matsushime H et al. Cell 1991;65:701-713.
- 13Zopf D et al. Cancer Med 2016;5:3176-3185.
- 14Wilhelm SM et al. Int J Cancer 2011;129:245-255.
- 15Abou-Elkacem L et al. Mol Cancer Ther 2013;12:1322-1331.
- 16Schmieder R et al. Int J Cancer 2014;135:1487-1496.
- 17Takigawa H et al. Cancer Sci 2016;107:601-608.